Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Wee Care Pediatrics

Neither a doctor nor a teaching hospital

Research payments

$2,744,451

536 payments

Through program year 2025, Wee Care Pediatrics is reported as receiving $2,744,451 in research payments, across 536 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $8,203 5
2024 Research $251,936 8
2023 Research $367,166 4
2022 Research $30,131 7
2021 Research $396,544 137
2020 Research $721,464 208
2019 Research $969,008 167

Breakdown

Who paid Research payments · program years 2019–2025
  1. Merck Sharp & Dohme Corporation $2,599,979 330 payments
  2. Pfizer Inc. $98,820 202 payments
  3. GlaxoSmithKline, LLC. $45,651 4 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety and Tolerability of V114 in Healthy Infants PNEU-LINK $1,007,703 44 payments
  2. A Phase 2b,3 Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-1654 in Healthy Pre-Term and Full-Term Infants $736,742 20 payments
  3. A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED $719,552 36 payments
  4. A Phase 3 Randomized Doubleblind Trial to Evaluate the Safety and Immunogenicity of A 20Valent Pneumococcal Conjugate Vaccine in Healthy Infants $98,562 200 payments
  5. A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED $61,005 126 payments
  6. A Phase 2, Randomized, Double-Blind, Multi-Dose, Dose Finding Study to $45,651 4 payments
  7. A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety and Tolerability of V114 in Healthy Infants PNEU-LINK $17,919 34 payments
  8. A Phase 1, Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of an Expanded Pneumococcal Conjugate Vaccine in Healthy Infants $16,666 1 payment
  9. A Phase III, Double-Blind, Randomized, Multicenter, Controlled Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX Passage Extension 34 PE34 Process Administered Concomitantly with M-M-R II $9,735 9 payments
  10. A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety and Tolerability of V114 in Healthy Infants (PNEU-LINK) $8,371 15 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record